HEATHER T GARRETT

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner ROGERSVILLE, AL NPI 1316144264

General Payments — all program years on this page

$1,511.12

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 99
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $347.63 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $347.6319

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Lilly USA, LLC $134.138
Acerta Pharma LLC $56.083
ABBVIE INC. $53.553
Novo Nordisk AS $29.421
Lundbeck LLC $20.511
Exact Sciences Corporation $20.101
GlaxoSmithKline, LLC. $17.381
Phathom Pharmaceuticals, Inc. $16.461

By program year

Program yearAmountRecords
2021 $224.1012
2022 $414.2231
2023 $525.1737
2024 $347.6319

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100442703 Novo Nordisk Inc $29.42 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104401579 AstraZeneca Pharmaceuticals LP $19.66 11/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104651379 AstraZeneca Pharmaceuticals LP $20.13 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105586128 AstraZeneca Pharmaceuticals LP $16.29 06/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107153060 ABBVIE INC. $15.59 03/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107153062 ABBVIE INC. $22.55 04/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1107153064 ABBVIE INC. $15.41 05/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114559813 Exact Sciences Corporation $20.10 11/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116213576 GlaxoSmithKline, LLC. $17.38 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135652771 Lilly USA, LLC $13.44 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135678617 Lilly USA, LLC $6.79 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135678619 Lilly USA, LLC $18.91 02/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135678621 Lilly USA, LLC $24.99 06/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135680151 Lilly USA, LLC $15.28 01/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135690946 Lilly USA, LLC $25.08 04/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135690948 Lilly USA, LLC $16.82 05/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135690950 Lilly USA, LLC $12.82 01/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146024851 Lundbeck LLC $20.51 11/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1151167546 Phathom Pharmaceuticals, Inc. $16.46 03/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.